Within four hours of a single intranasal dose, Semax produces measurable increases in BDNF mRNA in the rat hippocampus — a speed of neurotrophic induction that puts it in a category occupied by very few molecules. What makes this more remarkable is that Semax is a fragment of adrenocorticotropic hormone (ACTH) stripped of all hormonal activity: it cannot stimulate cortisol, cannot bind melanocortin receptors with meaningful affinity, and yet it reliably modulates dopaminergic tone, serotonergic signaling, and synaptic plasticity in the prefrontal cortex.
What Is Semax?
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro, corresponding to amino acids 4-7 of adrenocorticotropic hormone (ACTH(4-7)) with a C-terminal Pro-Gly-Pro tripeptide added to confer enzymatic stability. It was developed in the 1980s at the Institute of Molecular Genetics of the Russian Academy of Sciences and registered in Russia in 1996 for cerebrovascular and cognitive indications. The Pro-Gly-Pro extension dramatically extends the peptide’s half-life in plasma and cerebrospinal fluid compared to native ACTH(4-10), allowing intranasal administration to produce sustained central effects.[1]
Unlike full-length ACTH, Semax lacks the C-terminal residues required for melanocortin receptor activation and steroidogenesis. This dissociation of hormonal from neurotropic activity is the central pharmacological feature of the molecule — it retains the cognitive and neuroprotective properties of the ACTH fragment while shedding the HPA-axis effects.
How Semax Works
BDNF and NGF Transcription: The most well-characterized mechanism of Semax is rapid upregulation of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) gene expression in the hippocampus and frontal cortex. A single intranasal dose produces measurable increases in BDNF and TrkB receptor mRNA within hours, with downstream protein elevation supporting synaptic plasticity and neuronal survival.[2]
Dopaminergic Modulation: Semax influences dopaminergic tone in the striatum and prefrontal cortex without acting as a direct receptor agonist. Microdialysis studies show altered dopamine turnover following administration, and the peptide potentiates the behavioral effects of dopaminergic agents — suggesting modulation at the level of synthesis, release, or reuptake rather than direct receptor binding.[3]
Serotonergic and Enkephalinergic Effects: Beyond dopamine, Semax inhibits the degradation of enkephalins by blocking enkephalinase activity, prolonging endogenous opioid signaling. It also modulates serotonergic transmission in cortical regions, contributing to anxiolytic and mood-stabilizing effects observed in preclinical models.[4]
Melanocortin Receptor Interaction (Low Affinity): While Semax does not produce classical melanocortin effects, some evidence suggests weak interaction with MC4R or related receptors in CNS tissue. This interaction is mechanistically distinct from steroidogenic ACTH signaling and is thought to contribute to the peptide’s effects on attention and arousal.[1]
Intranasal Delivery and CNS Penetration: Semax is administered intranasally because the peptide bypasses first-pass hepatic metabolism and reaches the CNS via olfactory and trigeminal nerve pathways. The Pro-Gly-Pro C-terminal extension protects the active core from rapid proteolysis, extending the biological half-life relative to native ACTH fragments.
Research Findings
Ischemic Stroke Recovery: Semax has been studied extensively in the context of acute ischemic stroke, where it is used clinically in Russia as an adjunct therapy. Gene expression analyses in rat models of focal cerebral ischemia demonstrate that Semax modulates expression of genes related to inflammation, vascular remodeling, and neuronal survival within hours of administration following middle cerebral artery occlusion.[5]
BDNF and Synaptic Plasticity: Work by Dolotov and colleagues demonstrated that Semax rapidly increases BDNF protein levels in the rat hippocampus, with downstream activation of TrkB-mediated signaling cascades. The kinetics — measurable effects within 30 to 90 minutes — distinguish Semax from pharmacological agents that induce BDNF only after chronic administration.[2]
Cognitive Performance and Attention: Russian clinical trials in patients with cognitive impairment, attention deficits, and post-stroke cognitive dysfunction have reported improvements in attention, short-term memory, and executive function. While much of this literature is published in Russian-language journals and methodological standards vary, the consistent signal across studies aligns with the preclinical neurotrophic data.
Neuroprotection in Optic Nerve Injury: Semax has been investigated in optic neuropathy and glaucoma models, where its neurotrophic effects translate to protection of retinal ganglion cells. This application reflects the broader principle that BDNF and NGF upregulation supports neuronal survival across multiple CNS tissues.
Safety Profile
Semax has a favorable safety profile in clinical use spanning more than two decades in Russia. Because the molecule lacks the C-terminal residues required for melanocortin receptor activation, it does not stimulate cortisol production or HPA-axis activity at therapeutic doses — a critical distinction from native ACTH fragments. Adverse effects reported in clinical studies are typically mild and include transient nasal irritation from the intranasal vehicle.
The peptide has not been approved by the U.S. FDA or European Medicines Agency, and most rigorous pharmacovigilance data exist within the Russian healthcare system. Long-term safety in chronic high-dose use, interactions with psychotropic medications, and effects in specific populations (pregnancy, pediatric use outside approved indications) remain incompletely characterized in the international literature. The neurotrophic mechanism also raises theoretical questions about effects in patients with active malignancy, given the role of BDNF/TrkB signaling in some tumor biology — though no clinical signal has emerged.
Semax vs Other Cognitive Approaches
vs. Racetams: Piracetam and related racetams modulate cholinergic and glutamatergic transmission but produce minimal direct effects on neurotrophin expression. Semax operates upstream, driving the transcriptional machinery that supports long-term synaptic remodeling rather than modulating moment-to-moment neurotransmission.
vs. Stimulants: Methylphenidate and amphetamines acutely increase synaptic dopamine and norepinephrine, producing rapid but transient enhancement of attention. Semax modulates dopaminergic tone without acting as a direct reuptake inhibitor or releaser, and its primary effects appear to be on neurotrophic support rather than acute catecholamine surge — a profile that may favor sustained executive function without tolerance or withdrawal phenomena.
vs. SSRIs: Selective serotonin reuptake inhibitors eventually increase BDNF through chronic dosing, with weeks required to produce measurable neurotrophic effects. Semax produces BDNF elevation within hours, suggesting it accesses the transcriptional pathway more directly — though the durability and clinical translation of this rapid induction require further study.
vs. Selank: Selank, another Russian-developed regulatory peptide, shares the heptapeptide structure and intranasal route but derives from tuftsin rather than ACTH. Selank emphasizes anxiolytic and immunomodulatory effects via GABAergic and enkephalinergic pathways, whereas Semax is more strongly weighted toward neurotrophic and dopaminergic mechanisms. The two are sometimes studied in combination for complementary effects on mood and cognition.
References
- Ashmarin IP, Nezavibatko VN, Levitskaya NG, et al. “Design and investigation of an ACTH(4-10) analog lacking D-amino acids and hydrophobic radicals.” Neuroscience and Behavioral Physiology. 1995;25(3):234-240.
- Dolotov OV, Karpenko EA, Inozemtseva LS, et al. “Semax, an analog of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain.” Journal of Neurochemistry. 2006;97 Suppl 1:82-86.
- Eremin KO, Kudrin VS, Saransaari P, et al. “Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents.” Neurochemical Research. 2005;30(12):1493-1500.
- Kost NV, Sokolov OYu, Gabaeva MV, et al. “Semax and Pro-Gly-Pro activate the actions of the enkephalins and exert an anxiolytic effect.” Bulletin of Experimental Biology and Medicine. 2001;132(5):1078-1081.
- Medvedeva EV, Dmitrieva VG, Povarova OV, et al. “The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia.” Molecular Biology. 2014;48(1):105-114.
